{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Number of Participants With AEs and SAEs-Part 1 BID","type":"PRIMARY","unitOfMeasure":"Participants"}